Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074489 | 0.85 | HTR6 (0.50) | HTR6MERTK | |
| SCHEMBL4070322 | 0.85 | HTR6 (0.50) | HTR6MERTK | |
| Hydrochloric Acid SCHEMBL4073491 | 0.84 | HTR6 (0.49) | HTR6MERTK | |
| SCHEMBL4068604 | 0.80 | HTR6 (0.43) | HTR6 | |
| SCHEMBL4074348 | 0.80 | HTR6 (0.41) | HTR6MERTK | |
| SCHEMBL4071360 | 0.77 | HTR6 (0.40) | HTR6 | |
| SCHEMBL4819457 | 0.77 | HTR6 (0.46) | HTR6MERTKCHRNB2CHRNA4 | |
| SCHEMBL4817049 | 0.74 | KMT2A (0.46) | HTR6MERTKCHRNB2CHRNA4 | |
| SCHEMBL4815152 | 0.69 | DRD2 (0.37) | HTR6CHRNB2CHRNA4 | |
| SCHEMBL4808285 | 0.69 | DRD2 (0.39) | HTR6CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589108-B2 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| US-6995176-B2 | 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030593-A1 | 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR5A | HTR6 1/4885MERTK 1944/4885CHRNB2 110/4885 |
| US-20040024023-A1 | 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3A, HTR1A | HTR6 1/4885MERTK 1724/4885CHRNB2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.